<italic toggle="yes">In Vivo</italic> Targeting of <named-content content-type="genus-species">Clostridioides difficile</named-content> Using Phage-Delivered CRISPR-Cas3 Antimicrobials

<italic toggle="yes">In Vivo</italic> Targeting of <named-content content-type="genus-species">Clostridioides difficile</named-content> Using Phage-Delivered CRISPR-Cas3 Antimicrobials

ABSTRACT Clostridioides difficile is an important nosocomial pathogen that causes approximately 500,000 cases of C. difficile infection (CDI) and 29,000 deaths annually in the United States. Antibiotic use is a major risk factor for CDI because broad-spectrum antimicrobials disrupt the indigenous gu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kurt Selle, Joshua R. Fletcher, Hannah Tuson, Daniel S. Schmitt, Lana McMillan, Gowrinarayani S. Vridhambal, Alissa J. Rivera, Stephanie A. Montgomery, Louis-Charles Fortier, Rodolphe Barrangou, Casey M. Theriot, David G. Ousterout
Format: article
Langue:EN
Publié: American Society for Microbiology 2020
Sujets:
Clostridioides difficile
CRISPR-Cas
Cas3
phage
lysogeny
CRISPR
Microbiology
QR1-502
Accès en ligne:https://doaj.org/article/05d3dd5ddad5489e8af88e62d8ba3612
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/05d3dd5ddad5489e8af88e62d8ba3612

Documents similaires